Vaderis Therapeutics closed an oversubscribed $152 million Series B financing and launched its global Phase III study HEROIC in hereditary hemorrhagic telangiectasia (HHT). The trial evaluates engasertib (VAD-044), an oral allosteric AKT inhibitor designed specifically for HHT pathophysiology. Vaderis said HEROIC is the first Phase III study using an HHT-developed molecule, and it framed the dual financing and trial start as a step toward potential US regulatory approval for the investigational therapy. The company also identified its financing co-leads and participating investors, positioning the round to fund operations through approval timelines. With no approved therapies currently available for HHT worldwide, the company is positioning engasertib as a potential disease-modifying option. The Phase III launch now sets up key clinical readouts that will determine whether the program can move into regulatory review.